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patients recruited through an agency, Twitter and Asthma UK’s website. Participants 
had experienced a NCS and a SS < 3 years previously. Medication history and Asthma 
Control Test (ACT) scores were collected. Interviews were audio-recorded, and the-
matically analysed. Results: The sample was 69% Caucasian, with six males and 
seven females, and a mean age= 47. Most were working full time or retired, and had 
many years since asthma diagnosis (mean= 22 years). NCS were related to reliever 
(n= 7), preventer (n= 4) or both (n= 2) medications with the most common NCS from 
one brand to another (n= 4). Participants reported negative feelings, difficulty using 
the medication and ineffective symptom control. Most participants used the NCS 
medication < 6 months (range < 24 hours–2 years). The SS for most was a return to 
their original pre-NCS medication (n= 11). Although most found getting their SS 
straightforward, this required at least two HCP visits for half the sample, and took 
up to two months to obtain. Most expected symptoms to improve following the SS 
but nine participants still had sub-optimal ACT scores. Lasting impacts included 
damaged relationships with HCPs, strong views about NCS and concern about NCS 
reoccurrence. ConClusions: Failure to inform and involve patients in medication 
changes can have lasting impacts. It is important to note that NCS can incur costs 
associated with rejection of medicines and additional consultations, thus negating 
any attempt at cost saving.
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objeCtives: To evaluate the degree to which the officially pre-determined cost 
and average length of stay (ALoS) per selected KEN-DRG reflect actual resource 
use and to investigate other factors (e. g. size, type and location of hospital) corre-
lated with charges and ALoS. Methods: Data were from the Health Regions data 
base and included discharges, ALoS, and charges in NHS Hospitals for the selected 
KEN-DRGs. Predetermined ALoS and cost per KEN-DRG were derived from Gazette 
946/27/03/2012. Continuous variables did not follow normal distribution, so non 
parametric methods (Spearman’s correlation coefficient, Kruskal-Wallis test and 
Mann-Whitney test) were used. A two sided p-value ≤ 0.05 was considered statis-
tically significant. Results: Higher length of stay compared with the officially 
pre-determined was found for Chronic Obstructive Pulmonary Disease (COPD) 
with complications (10.8 vs 9 days), Bronchitis & Asthma with complications (5.8 
vs 4 days), Bronchitis & Asthma without complications (2.7 vs 2 days) and Breast 
Cancer with complications (7.9 vs 5 days). Consequently, officially pre-determined 
cost for Breast Cancer with complications (€ 965), Bronchitis & Asthma with com-
plications (€ 792) and COPD with complications (€ 1,446) represents less than 90% 
of total hospital charges (total actual average charge: € 1,186; € 929; € 1,634 respec-
tively). However, for the rest of the DRGs, under study, there were none or limited 
additional hospital charges. For all KEN-DRGs, size and population density was 
positively correlated with total charges (rs= 0.12, p= 0.018; median for Athens = 863 
& semi-urban= 752 p= 0.09 respectively). Moreover, for Bronchitis & Asthma with and 
without complications, population density was found to be positively correlated 
with ALoS (median for urban areas= 5.1 and semi-urban= 4.7; p= 0.09 and median 
for urban areas= 3 and semi-urban= 2.5; p= 0.03 respectively). ConClusions: The 
introduction of KEN-DRGs was a useful first step to modernize the hospital reim-
bursement system. However, further revisions are required in order for KEN-DRGs 
to become more useful.
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objeCtives: Asthma is under-diagnosed and under-treated in elderly, and utili-
zation of asthma medications in this population is not well characterized. This 
study describes utilization patterns of asthma medications in newly diagnosed 
≥ 50 patients. Methods: Medicare enrollees are followed for 12 months after first 
asthma diagnosis between Q1 2004- Q3 2012 (ICD-9-CM code: 493*). Treatment pat-
tern analysis was applied to initiators of asthma medications. Patients with > 1 
prescription of second-line therapy following exposure to first-line therapy are con-
sidered therapy switchers or augmenters. Patients with history of chronic obstruc-
tive pulmonary disease are excluded (ICD-9-CM codes: 490, 491*, 492*, 494*, 495* 
& 496). Results: Among 126,176 elderlies with asthma, 24,021 initiated asthma 
therapy within 12 months of asthma diagnosis (70% women, median age 70 years). 
319 (1.3%) continued therapy with one drug class (first-line therapy); 13,940 (58%) 
discontinued first-line therapy; 3,469 (14.4%) switched to another drug class (sec-
ond-line therapy); and 6,293 (26.2%) added second-line therapy (augmented). About 
34% of patients initiated therapy with inhaled short-acting beta-agonists (SABA); 
majority of them either discontinued SABA or added a controller medication. 19% 
of elderly patients started with oral corticosteroids after asthma diagnosis, 77% 
discontinued them and 12% switched to another asthma controller. Among con-
troller medications, inhaled corticosteroids (ICS) /long-acting beta-agonists (LABA) 
combination therapy, ICS monotherapy, and leukotriene antagonists respectively 
accounted for 19%, 12%, and 11% of treatment initiators. The majority of these anti-
are directly and indirectly linked with HRQoL of TB patients. Methods: A prospec-
tive cross-sectional study was conducted at a tertiary care hospital in a province 
of Pakistan, the Punjab. Data was collected by using WHOQOL-BREF question-
naire (Urdu version, pretested for reliability and validity) by means of face-to-face 
interviews and where possible by gender-based focus group sessions. In addition, 
facilitators also used few open-ended questions in order to get patients’ demo-
graphic and socioeconomic data. Participants were also asked to share their per-
sonal experiences of being diagnosed and treated with TB and what impact it had 
on their life style. All obtained data were analyzed using descriptive and inferen-
tial statistics. Results: The overall Cronbach’s alpha coefficient of the revalidated 
WHOQOL-BREF questionnaire was 0.785. The confirmatory factor analysis also pro-
vided an acceptable fit to a four-factor model in the studied sample. The scores for 
negative feelings, blue mood, depression, living place, personal relationships and 
sex life were significantly different in the psychological health and social relations 
domains. Age, gender and physical exercise were also significantly associated with 
the HRQoL of the patients. ConClusions: The WHOQOL-BREF was reliable and 
valid in the assessment of the HRQoL of TB patients in Pakistan. Despite the ability 
to cure TB, there was a significant impact on HRQoL of the TB patients. Till today, 
much attention is spent on curative and preventative mechanisms whereas the 
impact of TB on HRQoL is often neglected.
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objeCtives: To assess published data on perennial allergic rhinitis/house dust 
mite allergic (PAR) patients and seasonal allergic rhinitis/grass pollen allergic (SAR) 
patients in order to establish the burden of allergic rhinitis (AR) and allergic asthma 
from both a quality of life (QoL) and cost perspective. Methods: A systematic liter-
ature review was conducted using Medline and Embase in eight pre-specified coun-
tries for the time period of January 2000 to January 2014. Search terms were related 
to QoL and/or cost. A total of 2963 abstracts and titles were identified. 50 abstracts 
met predefined criteria and provided data for calculations and collation. Results: 
Based on the RQLQ, the overall QoL of PAR patients was significantly worse than that 
of SAR patients (2.73 ± 0.12 cf. 2.04 ± 0.18, p≤ 0.001). In general, practical problems 
(mean: 3.80 ± SE: 0.08) and activities (mean: 3.70 ± SE: 0.11) were the most affected 
domains. Measured by the physical component score from the SF-36 questionnaire, 
the overall QoL of PAR patients was worse (p= 0.002) than that of SAR patients (49.06 
± 1.26 cf. 64.19 ± 7.89). For both PAR and SAR patients, domains measured by the 
SF-36 showed that vitality (mean: 59.95 ± SE: 3.24) was the most affected domain. 
Based on RQLQ, allergy immunotherapy improves eye symptoms, nasal symptoms, 
activities and practical problems the most in grass allergic patients. Direct compari-
son of total direct and indirect costs was complicated by differences in individual 
costs assessed among studies, however, the primary burden of costs is indirect 
and caused by high absenteeism and presenteeism. ConClusions: The QoL and 
economic burden of AR was substantial in the countries included in this review. 
However, limitations regarding the number of studies per country, heterogeneity 
between studies, and the lack of presented data have restricted the conclusions 
that could be drawn.
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objeCtives: To determine the Quality of Life (QoL) of bronchial asthma patients in 
a tertiary care teaching hospital at baseline and at follow up. Methods: The study 
was conducted for a period of 6 months among 100 bronchial asthma patients, with 
and without co-morbidities, admitted to the pulmonary and medicine wards in 
the university hospital after obtaining the ethical clearance. The quality of life was 
assessed using Asthma Quality Of life Questionnaire (AQLQ). Patients were followed 
up after 4weeks from the date of discharge. Statistical analysis was performed using 
SPSS version 20. Results: The mean age of the study population was 53.30±14.59 
having 61% of the patients as females. Data was analyzed by Wilcoxon signed rank 
test. The total score of Qol at follow up (5.94 ±0.76) showed an improvement with 
a P value < 0.0001 (wilcoxon signed rank t test) when compared with baseline (3.92 
± 1.04). A significant improvement in symptoms was seen at follow up (6.05 ± 0.82) 
from baseline (3.93 ± 1.14). The activity limitation improved with a P value < 0.0001 
(Wilcoxon signed rank t test) from baseline (4.00 ± 1.08) to follow up (5.92 ± 0.83). At 
follow up (5.97 ± 0.82) the emotional function showed an enhancement on compar-
ing with baseline (3.92 ± 1.14). The environmental stimuli showed no significant 
changes at baseline (3.66 ± 1.29) and follow up (3.84 ± 1.34). ConClusions: The 
results of the study suggests that clinical pharmacists have a major role in improv-
ing patient knowledge and thereby significantly improve the quality of life of the 
patient.
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objeCtives: Patient satisfaction with asthma treatment is associated with bet-
ter adherence and achievement of treatment goals. While medication changes are 
sometimes instigated for clinical or financial reasons, changes without patients’ 
knowledge or involvement (‘non-consented switch’ [NCS]) can impact symptom 
control and patient-health care provider (HCP) relationships. This study explored 
experiences of patients who had a NCS and subsequently requested and received a 
second switch (SS). Methods: Interviews were conducted with 13 UK adult asthma 
